Skip to content Skip to footer

PROVIREX receives funding from IFB Hamburg to develop novel HIV therapy

PROVIREX Genome Editing Therapies GmbH Hamburg and the University Medical Centre Hamburg-Eppendorf will receive R&D funding from the Hamburg Investment and Development Bank (IFB Hamburg) for the next four years, as part of the Programme for Innovation (PROFI). The research object is to develop novel methods for directly administering of antiviral therapies based on genome editing, in order to provide scalable, i.e. broadly applicable, healing strategies for people with HIV and potentially other viral infections. The project is being carried out in cooperation with the University Medical Center Hamburg-Eppendorf (UKE). Read here the original Press Release.

Genome Editing Therapies GmbH

Luruper Hauptstraße 1
22547 Hamburg


Copyright © PROVIREX Genome Editing Therapies GmbH 2023